New River reiterated by Merrill Lynch at buy

New River Pharmaceuticals Inc. was reiterated by Merrill Lynch analyst David Munno at a buy rating with a price target on the stock of $49 per share, citing among other things the likelihood that its partnered drug with Shire Pharmaceuticals plc, NRP104, will become the new market leader to treat Attention Deficit Hyperactivity Disorder. New River shares Tuesday were up $1.03, or 2.52%, at $41.97 on volume of 69,617 shares versus the three-month running average of 67,367.6 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.